RhumbLine Advisers’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$51.7M Sell
768,165
-4,392
-0.6% -$293K 0.04% 377
2026
Q1
$48.5M Sell
772,557
-3,194
-0.4% -$222K 0.04% 369
2025
Q4
$51.5M Sell
775,751
-24,806
-3% -$1.6M 0.04% 349
2025
Q3
$53.9M Sell
800,557
-9,731
-1% -$770K 0.04% 342
2025
Q2
$70.7M Buy
810,288
+485
+0.1% +$38K 0.06% 260
2025
Q1
$55.3M Buy
809,803
+33,574
+4% +$2.74M 0.05% 304
2024
Q4
$60.4M Sell
776,229
-29,434
-4% -$2.18M 0.05% 285
2024
Q3
$54M Buy
805,663
+306
+0% +$25.1K 0.05% 320
2024
Q2
$91.3M Buy
805,357
+17,817
+2% +$2.25M 0.09% 188
2024
Q1
$109M Buy
787,540
+9,661
+1% +$1.21M 0.1% 166
2023
Q4
$96.5M Sell
777,879
-11,376
-1% -$1.16M 0.1% 176
2023
Q3
$73.6M Buy
789,255
+133
+0% +$15K 0.09% 207
2023
Q2
$101M Buy
789,122
+5,267
+0.7% +$637K 0.11% 153
2023
Q1
$91.1M Buy
783,855
+47,461
+6% +$5.31M 0.11% 158
2022
Q4
$83.4M Buy
736,394
+15,818
+2% +$1.74M 0.11% 172
2022
Q3
$58M Buy
720,576
+12,062
+2% +$1.02M 0.09% 213
2022
Q2
$52.8M Buy
708,514
+41,990
+6% +$3.83M 0.08% 238
2022
Q1
$85.2M Sell
666,524
-968
-0.1% -$106K 0.11% 161
2021
Q4
$89.6M Buy
667,492
+3,300
+0.5% +$474K 0.11% 158
2021
Q3
$90.8M Sell
664,192
-2,492
-0.4% -$314K 0.12% 142
2021
Q2
$71.2M Sell
666,684
-5,100
-0.8% -$490K 0.09% 187
2021
Q1
$60.4M Sell
671,784
-26,544
-4% -$2.49M 0.08% 211
2020
Q4
$64.5M Buy
698,328
+4,452
+0.6% +$398K 0.09% 195
2020
Q3
$71.5M Buy
693,876
+10,068
+1% +$1.05M 0.11% 158
2020
Q2
$69.3M Buy
683,808
+301,732
+79% +$27M 0.12% 157
2020
Q1
$25.7M Sell
382,076
-6,788
-2% -$422K 0.05% 320
2019
Q4
$21.3M Buy
388,864
+8,208
+2% +$389K 0.04% 460
2019
Q3
$14.2M Sell
380,656
-3,300
-0.9% -$128K 0.03% 596
2019
Q2
$14.4M Sell
383,956
-14,428
-4% -$454K 0.03% 590
2019
Q1
$11.9M Sell
398,384
-6,304
-2% -$222K 0.02% 677
2018
Q4
$12.1M Sell
404,688
-752
-0.2% -$23.9K 0.03% 606
2018
Q3
$14.5M Buy
405,440
+760
+0.2% +$23.6K 0.03% 538
2018
Q2
$9.61M Buy
404,680
+9,268
+2% +$196K 0.02% 702
2018
Q1
$7.33M Sell
395,412
-11,632
-3% -$172K 0.02% 809
2017
Q4
$5.84M Sell
407,044
-7,472
-2% -$97.1K 0.01% 972
2017
Q3
$5.07M Sell
414,516
-14,244
-3% -$252K 0.01% 1029
2017
Q2
$7.84M Buy
428,760
+692
+0.2% +$12.8K 0.02% 746
2017
Q1
$9.07M Buy
428,068
+12,632
+3% +$247K 0.02% 691
2016
Q4
$6.2M Buy
415,436
+18,860
+5% +$334K 0.02% 832
2016
Q3
$8.69M Buy
396,576
+18,532
+5% +$412K 0.02% 619
2016
Q2
$7.5M Buy
378,044
+31,068
+9% +$529K 0.02% 642
2016
Q1
$5.89M Sell
346,976
-8,400
-2% -$140K 0.02% 752
2015
Q4
$7.28M Buy
355,376
+1,920
+0.5% +$40K 0.02% 645
2015
Q3
$7.59M Buy
353,456
+13,480
+4% +$301K 0.03% 616
2015
Q2
$6.8M Sell
339,976
-10,884
-3% -$191K 0.02% 690
2015
Q1
$5.47M Buy
350,860
+46,340
+15% +$700K 0.02% 791
2014
Q4
$4.19M Sell
304,520
-5,460
-2% -$66.8K 0.01% 887
2014
Q3
$3.1M Sell
309,980
-9,320
-3% -$95.3K 0.01% 1032
2014
Q2
$3.17M Buy
319,300
+11,908
+4% +$106K 0.01% 1072
2014
Q1
$3.18M Sell
307,392
-8,840
-3% -$91.4K 0.01% 1063
2013
Q4
$2.8M Buy
316,232
+7,080
+2% +$56K 0.01% 1156
2013
Q3
$2.18M Sell
309,152
-5,332
-2% -$33.8K 0.01% 1281
2013
Q2
$1.76M Buy
+314,484
New +$1.51M 0.01% 1392

Other funds holding DXCM

RhumbLine Advisers's DXCM Position: Q2 2026 in Review

RhumbLine Advisers reduced its DexCom (DXCM) stake by 0.57% in Q2 2026, selling an estimated $293K and leaving 768,165 shares worth $51.7M. The position accounts for 0.04% of the portfolio, ranked #377.

RhumbLine Advisers first reported a position in DXCM in Q2 2013 and has held it in 53 quarters since. The position peaked at $109M in Q1 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • RhumbLine Advisers held 768,165 shares of DexCom worth $51.7M as of Q2 2026.
  • RhumbLine Advisers sold 4,392 DexCom shares in Q2 2026, an estimated $293K.
  • DexCom made up 0.04% of RhumbLine Advisers's portfolio in Q2 2026, its #377 holding.
  • RhumbLine Advisers first reported a position in DexCom in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's DexCom position peaked at $109M in Q1 2024.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.